To determine whether AKT3 or FGFR2 can serve as potential targets, we first constructed the F0 generation PDX tumor models with biospecimens from PPLELC patients and transplanted into F1 generation PDXs for efficacy experiments. The gene discussed is AKT3; the disease is neoplasm.